<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01706627</url>
  </required_header>
  <id_info>
    <org_study_id>MIRCIT</org_study_id>
    <secondary_id>TRF</secondary_id>
    <nct_id>NCT01706627</nct_id>
  </id_info>
  <brief_title>Melatonin In Reduction of Chemotherapy-Induced Toxicity (MIRCIT) Trial</brief_title>
  <acronym>MIRCIT</acronym>
  <official_title>Melatonin In Cancer Patients Receiving Chemotherapy: A Randomized, Double Blind, Placebo, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Khon Kaen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Srinagarind Hospital, Khon Kaen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Khon Kaen Hospital, Khon Kaen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Drug House Ltd., Bangkok</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thailand Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Khon Kaen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Meta-analysis of previous studies have shown that melatonin is a beneficial adjutant for
      reducing chemotherapy-induced toxicity; however no randomized, double-blind, placebo
      controlled trials have been conducted. This study evaluates the effect of melatonin in
      improving quality of life and reducing chemotherapy-induced toxicity in advanced cancer
      patients. This is a multi-center, randomized, double-blind, placebo controlled trial
      conducted in patients with histologically proven advanced non small cell lung, breast, head
      and neck or sarcoma cancer. Mixed-block randomization, stratified by center and treatment
      scheme is used to divide eligible patients into three groups: melatonin 20 mg, 10 mg or
      matched placebo. The patients are required to take the studied drugs at night (after 21.00
      pm) on the first day of chemotherapy and continue daily for six months. Standard treatment is
      chemotherapy according to each center's standard protocol. Study endpoints are QOL (FACT),
      adverse event frequency (CTCAE), oxidative stress status, melatonin level, and survival.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Life (FACT)</measure>
    <time_frame>Change from baseline in total scores at 6 months after treatment</time_frame>
    <description>Self-reported questionnaires. FACT-L, FACT-B, FACT-H&amp;N and FACT-G Thai Version 4 has been previously validated. FACT-L, FACT-B, FACT-H&amp;N and FACT-G are used in lung, breast, head&amp;neck and sarcoma cancer patients, respectively. Change from baseline will be evaluated at 1,2,3 and 6 months after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Baseline and 1,2,3 and 6 months after treatment</time_frame>
    <description>CTCAE Version 4.3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress status</measure>
    <time_frame>Chemotherapy cycles 1,2,3,4</time_frame>
    <description>8-isoprostane and 8-hydroxydeoxyguanosine urine and MDA plasma analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Melatonin level</measure>
    <time_frame>Chemotherapy cycle 1,2,3 and 4</time_frame>
    <description>Blood, urine and saliva analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Over 4 years of the study</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">175</enrollment>
  <condition>Advanced Stage Cancer</condition>
  <arm_group>
    <arm_group_label>Matched placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo (identical formulation and delivery, without active ingredient)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug: 10 mg Melatonin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg melatonin gelatin capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug: 20 mg Melatonin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 mg melatonin gelatin capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10 mg Melatonin</intervention_name>
    <description>Active Comparator: Drug: Melatonin 10 mg</description>
    <arm_group_label>Drug: 10 mg Melatonin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20 mg Melatonin</intervention_name>
    <description>Active Comparator: Drug: Melatonin 20 mg</description>
    <arm_group_label>Drug: 20 mg Melatonin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matched placebo</intervention_name>
    <description>Matched placebo (identical formulation and delivery, without active ingredient)</description>
    <arm_group_label>Matched placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically proven advanced NSCLC, breast, head and neck, sarcoma cancer Eastern
             Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2

          -  platelet count ≥100,000 cells/mm3

          -  white blood cell count ≥ 3,000 cell/mm3

          -  hemoglobin ≥ 10 g/dL

          -  serum creatinine ≤ 1.5 mg/dL

          -  bilirubin ≤ 2 mg/dL

          -  AST ≤ 2.5 times upper limit of normal(ULN)for subjects without metastases or AST ≤ 2.5
             times UNL for those with liver metastases

          -  New York Heart Association grade ≤ 2

          -  written consent

        Exclusion Criteria:

          -  Patients who receive prior chemotherapy or biotherapy, radiotherapy or surgery within
             1 month preceding randomization

          -  Patients who have more than one type of cancer or brain metastasis were excluded from
             the trial.

          -  Patients with moderate neuropathy (CTCAE grade ≥ 2)

          -  Patients with an active infection, or uncontrolled complications (i.e. blood glucose &gt;
             200 mg/dL, uncontrolled hypertension, unstable angina, history of congestive heart
             failure or history of myocardial infarction within one year).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Khon Kaen Hospital</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Srinagarind Hospital</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2012</study_first_submitted>
  <study_first_submitted_qc>October 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2012</study_first_posted>
  <last_update_submitted>October 11, 2012</last_update_submitted>
  <last_update_submitted_qc>October 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Khon Kaen University</investigator_affiliation>
    <investigator_full_name>Nutjaree Pratheepawanit Johns</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>melatonin</keyword>
  <keyword>adjuvant therapy</keyword>
  <keyword>quality of life</keyword>
  <keyword>survival</keyword>
  <keyword>adverse events</keyword>
  <keyword>oxidative stress</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

